Search | IOVS | ARVO Journals

View

Showing 1 – 9 of 9

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract May 2006

OCT

K.D. Rosenberg; H.W. Flynn, Jr.; I.U. Scott; A.A. Moshfeghi

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):5275. doi:

ARVO Annual Meeting Abstract May 2005

Optical Coherence Tomography (OCT) Outcomes Following Systemic Bevacizumab (Avastin®) Therapy for Neovascular Age–Related Macular Degeneration

C.A. Puliafito; P.J. Rosenfeld; S. Michels; A.A. Moshfeghi; A.E. Fung; K.D. Rosenberg; A.S. Venkatraman

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):1376. doi:

ARVO Annual Meeting Abstract May 2005

Indocyanine Green Angiographic Outcomes Following Systemic Bevacizumab (Avastin®) Therapy for Neovascular Age–Related Macular Degeneration

K.D. Rosenberg; P.J. Rosenfeld; C.A. Puliafito; S. Michels; A.A. Moshfeghi; A.E. Fung

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):1377. doi:

ARVO Annual Meeting Abstract May 2005

Safety of Systemic Bevacizumab (Avastin®) Therapy for Neovascular Age–Related Macular Degeneration

S.M. Michels; P.J. Rosenfeld; C.A. Puliafito; A.A. Moshfeghi; A.E. Fung; K.D. Rosenberg; E.N. Marcus; A.S. Venkatraman

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):1378. doi:

ARVO Annual Meeting Abstract May 2005

Durability of Systemic Bevacizumab (Avastin®) Therapy for Neovascular Age–Related Macular Degeneration

A.A. Moshfeghi; P.J. Rosenfeld; C.A. Puliafito; S. Michels; A.E. Fung; K.D. Rosenberg; A.S. Venkatraman

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):1381. doi:

ARVO Annual Meeting Abstract May 2005

Fluorescein Angiographic Outcomes Following Systemic Bevacizumab (Avastin®) Therapy for Neovascular Age–Related Macular Degeneration

A.E. Fung; P.J. Rosenfeld; C.A. Puliafito; S. Michels; A.A. Moshfeghi; K.D. Rosenberg; E.N. Marcus; A.S. Venkatraman

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):1382. doi:

ARVO Annual Meeting Abstract May 2005

Systemic Bevacizumab (Avastin®) Therapy for Neovascular Age–Related Macular Degeneration (SANA) Study: Visual Acuity Outcomes

P.J. Rosenfeld; C.A. Puliafito; S. Michels; A.A. Moshfeghi; A.E. Fung; K.D. Rosenberg; E.N. Marcus; A.S. Venkatraman

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):2310. doi:

ARVO Annual Meeting Abstract May 2004

In Vitro Efficacy of Fluoroquinolones for Coagulase–Negative Staphylococcal Endophthalmitis Isolates

K.D. Rosenberg; H.W. Flynn Jr; I.U. Scott; P.M. Flynn; D. Miller

Invest. Ophthalmol. Vis. Sci.. 2004; 45(13):509. doi:

ARVO Annual Meeting Abstract May 2003

Continuous versus Non-continuous Laser Photocoagulation for the Treatment of Threshold Retinopathy of Prematurity

K.D. Rosenberg; T.G. Murray; A. Berrocal; E. Ysasaga; R. Loo; A. Aragon; M. Douglas; W. Feuer; G. Gregori

Invest. Ophthalmol. Vis. Sci.. 2003; 44(13):596. doi:

Advertisement